Search the Newsreel

Form 8K Atmus Filtration Technologies Inc For: 7 August By Investing.com

This article announces the filing of a Form 8K by Atmus Filtration Technologies Inc. for August 7th. It includes general market data and news headlines but does not provide specific details about the 8K filing itself. The article was published by Investing.com.

Earnings Flash (ATMU) Atmus Filtration Technologies Inc. Reports Q2 Revenue $527.9M, vs. FactSet Est of $507.0M

Atmus Filtration Technologies Inc. reported Q2 revenue of $527.9 million, surpassing FactSet's estimate of $507.0 million. The company's adjusted earnings and revenue increased, leading to an updated 2026 outlook with net sales expected to range from $1.98 billion to $2.03 billion and adjusted EPS …

Ultralife battery sales fell 3.7% as communications sales rose 39.3%

Atmus Filtration Technologies Reports Second Quarter 2026 Results

NASHVILLE, Tenn., August 07, 2026--(BUSINESS WIRE)--Atmus Filtration Technologies Inc. (Atmus; NYSE: ATMU), a global leader in filtration and media solutions, today reported financial results for its second quarter that ended June 30, 2026. Second Quarter Highlights Record Net sales of $528 million Power Solutions …

Janus Henderson Group PLC Sells 88,703 Shares of Altria Group, Inc. $MO

Janus Henderson Group PLC reduced its stake in Altria Group, Inc. (NYSE:MO) by 53.9% in the first quarter, selling 88,703 shares and retaining 76,002 shares valued at $5.02 million. Altria reported quarterly revenue of $5.36 billion but missed EPS estimates at $1.48, though it …

Ultrapar Participacoes S.A. (New) Stock 12‑Month Price Target Raised to $6.66, Implies 6% Upside

Analysts have raised the average 12-month price target for Ultrapar Participacoes S.A. (New) stock from $6.61 to $6.66, implying a potential 6% upside from its Aug. 5 closing price. The consensus rating among 14 analysts remains a "Buy," with 8 recommending Buy and 6 …

Assenagon Asset Management S.A. Buys 3,511,430 Shares of Altria Group, Inc. $MO

Assenagon Asset Management S.A. significantly increased its stake in Altria Group, Inc. by 3,691.2% during the second quarter, acquiring an additional 3,511,430 shares. The firm now owns 3,606,561 shares of Altria, valued at approximately $259.5 million, representing 0.22% of the company. Despite recent insider …

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

Analysts have issued a consensus rating of "Moderate Buy" for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), with 14 out of 18 analysts recommending the stock. The average 12-month price target is $57.82, significantly above the recent trading price of $25.82. The company recently reported better-than-expected quarterly …

Altria Group (NYSE:MO) Stock Price Down 1.2% - What's Next?

Altria Group (NYSE:MO) saw its stock price drop by 1.2% to $67.64, with trading volume 11% higher than average. Analysts maintain a "Hold" rating for the company, with a consensus price target of $70.78. Despite missing EPS estimates slightly, Altria's revenue narrowly beat expectations …

Is Wall Street Bullish or Bearish on Altria Group Stock?

Altria office sign in Virginia capital city tobacco business closeup By Kristina Blokhin Richmond, Virginia-based Altria Group, Inc. (MO), with a market capitalization of approximately $113.7 billion, is a leading U.S. tobacco company that manufactures and markets cigarettes, cigars, smokeless tobacco, oral nicotine pouches, …

Ultra Clean Holdings, Inc. $UCTT Shares Purchased by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Ultra Clean Holdings, Inc. (NASDAQ:UCTT) by 774.8% in Q1, now holding 77,983 shares valued at approximately $4.85 million. Institutional investors and hedge funds collectively own 96.06% of the company. Ultra Clean reported strong quarterly earnings, beating …

FMR LLC reports 6.5% Atmus Filtration (ATMU) stake in Schedule 13G/A

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 6.5% in Atmus Filtration Technologies Inc. (ATMU) common stock through a Schedule 13G/A filing. FMR LLC holds sole dispositive power over 5,316,383.48 shares and sole voting power over 5,313,078.35 shares. Abigail P. …

Ultra Clean Holdings (UCTT) Stock Sinks As Cash Burn Clouds Profit Return

The Top 5 Analyst Questions From Altria’s Q2 Earnings Call

Projeções de Resultados: Altria Group Inc (MO) — LPA e Crescimento de Receita

Ultragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burn

Earnings To Watch: Atmus Filtration Technologies (ATMU) Reports Q2 Results Tomorrow

Atmus Filtration Technologies (ATMU) is scheduled to report its Q2 earnings this Friday before market open. The company previously exceeded revenue expectations but met EBITDA estimates last quarter. Analysts anticipate a 12.1% year-over-year revenue growth for Q2, with positive sentiment in the gas and …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Altria Group, Inc. (MO) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Altria Group, Inc. (MO) after the company missed Q2 2026 earnings and revenue expectations and lowered its full-year guidance. The investigation focuses on whether Altria adequately disclosed risks related to its smoke-free product strategy …

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Altria Group (MO)

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altria Group (NYSE: MO) shareholders lost money on July 30, 2026 when the stock fell sharply after the Company reported second-quarter results that came in below Wall Street consensus on both earnings and revenue, and then …

Ultrapar Participacoes (UGP) to Post Earnings on Wednesday

Ultrapar Participacoes (NYSE:UGP) is set to release its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts forecasting earnings of $0.27 per share and revenue of $8.18 billion. The company's stock opened at $6.32, showing a substantial gain from its 12-month …

Ultra Clean Holdings, Inc. Stock 12‑Month Price Target Raised to $137, Implies 54% Upside

Ultra Clean Holdings, Inc. (UCTT) has seen its average 12-month price target raised from $116.4 to $137 by five analysts, with forecasts ranging from $120 to $150 per share. This updated target suggests a potential upside of approximately 54% from its August 3 closing …

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

Ultragenyx Pharmaceutical Inc. reported a narrower Q2 loss and increased revenue, surpassing FactSet estimates for both metrics. The company also reaffirmed its 2026 revenue guidance. This positive financial performance comes as the biopharmaceutical company continues to develop and commercialize treatments for rare and ultra-rare …

Ultra Clean Holdings (UCTT) Is Up 21.5% After AI-Fueled Beat And Raised Outlook Has The Bull Case Changed?

Ultra Clean Holdings (UCTT) recently reported strong Q2 2026 results, swinging to a net income and issuing raised Q3 guidance, attributing this to AI-driven semiconductor demand and its UCT 3.0 initiative. While the share price has increased significantly, the article discusses whether the current …

Ultragenyx Pharmaceutical Inc. Q2 2026: Revenue $214M, EPS $(0.90) — 10-Q Summary

Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 2026 results with revenue of $214M, a net loss of $92M, and diluted EPS of $(0.90), showing year-over-year improvement. Revenue growth was driven by Crysvita sales and royalties, and expanded demand for Evkeeza. The company also advanced its …

Ultragenyx Pharmaceutical (NASDAQ: RARE) posts $214M Q2 revenue, eyes 2027 profit

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultra Clean Holdings (UCTT) Stock Still Looks Undervalued Despite A 291% Run

Ultra Clean Holdings (UCTT) Lifted Q3 Guidance, Is The Stock Still Below Fair Value?

Ultragenyx Pharmaceutical Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical reported a record quarterly revenue of $214 million for Q2 2026, driven by strong performance across its commercial products Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. The company is preparing for potential FDA decisions on its first two gene therapies, DTX-401 for GSDIa and …

Ultra Clean Holdings, Inc. 2026: Revenue $644.9M, EPS $0.19— 10-Q Summary

Ultra Clean Holdings, Inc. reported strong financial results for the quarter ended 2026, with revenue increasing to $644.9M from $518.8M year-over-year. The company turned a net profit of $8.7M, a significant improvement from a $162M loss in the prior year, leading to diluted EPS …

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) reported $214 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 28.5%. EPS of -$0.90 for the same period compares to -$1.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $181.01 million, …

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides details on the company's financial performance. To access the full report and more in-depth analysis, readers are …

Ultra Clean (NASDAQ: UCTT) posts Q2 profit, issues $600M convertible notes

Ultra Clean Holdings, Inc. (NASDAQ: UCTT) reported a profitable Q2 2026, with revenue reaching $644.9 million, a 24.3% increase year-over-year, driven by strong demand in the semiconductor industry. The company returned to profit with a net income of $8.7 million, contrasting a significant loss …

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. reported strong financial results for the second quarter of 2026, with total revenue reaching $214 million and reaffirming its full-year revenue guidance of $730 million to $760 million. The company is on track for profitability in 2027 and anticipates significant catalysts …